Literature DB >> 3345537

Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan.

K Morikawa1, J Hamada, T Itaya, M Ishikawa, N Takeichi, M Hosokawa, H Kobayashi.   

Abstract

Rat fibrosarcoma cells infected with Friend leukemia virus (FV-KMT-17) grow for a short time and then regress spontaneously in syngeneic hosts. This regression mechanism was examined by analyzing the immunomodulating action of the antitumor drugs busulfan (BU) and cyclophosphamide (CY). In preliminary experiments, the optimum dosages of BU and CY for the enhancement of DTH responses to SRBC were 10 mg/kg and 40 mg/kg respectively. Treatment of rats with BU (10 mg/kg) on day 5 induced the regression of KMT-17 cells, while in contrast, the same drug delayed the spontaneous regression of FV-KMT-17 cells. Pretreatment with CY (40 mg/kg) on day 5 did not affect the growth of KMT-17 or FV-KMT-17 cells. After the same treatment schedule, BU inhibited humoral antibody formation against SRBC and against virus-associated antigen (VAA), NK cell activity, and ADCC effector cell activity. On the other hand, CY did not affect the activities of NK cells or ADCC effector cells, although it significantly augmented the DTH responses to SRBC and the production of antibody to VAA but had no effect on production of antibodies to SRBC. These results suggest that NK cells and ADCC may play an important role in the initial stage of the spontaneous regression of FV-KMT-17 cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345537     DOI: 10.1007/bf00199842

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Evidence that natural cytotoxicity and antibody-dependent cellular cytotoxicity are mediated in humans by the same effector cell populations.

Authors:  M O de Landazuri; A Silva; J Alvarez; R B Herberman
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

2.  Antigenic modification of rat tumor cells artificially infected with Friend virus in the primary autochthonous host.

Authors:  F Sendo; H Kaji; H Saito; H Kobayashi
Journal:  Gan       Date:  1970-06

3.  Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide.

Authors:  M Terishimna; N Takeichi; K Suzuki; T Itaya; E Gotohoda; H Kobayashi
Journal:  Tohoku J Exp Med       Date:  1980-11       Impact factor: 1.848

4.  Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay.

Authors:  T P Bradley; B Bonavida
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Augmentation of specific cell-mediated immune responses to tumor cells in tumor-bearing rats pretreated wih the antileukemia drug busulfan.

Authors:  Y Mizushima; F Sendo; T Miyake; H Kobayashi
Journal:  J Natl Cancer Inst       Date:  1981-04       Impact factor: 13.506

6.  Increased sensitivity of murine leukemia virus-infected tumor cells to lymphocyte-mediated cytotoxicity.

Authors:  M Kasai; H Yamaguchi; M Hosokawa; Y Mizushima; H Kobayashi
Journal:  J Natl Cancer Inst       Date:  1981-08       Impact factor: 13.506

7.  Enhancement of antitumor transplantation resistance in rats by appropriately timed administration of busulfan.

Authors:  Y Mizushima; F Sendo; N Takeichi; M Hosohawa; H Kobayashi
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

8.  Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice.

Authors:  N Minato; B R Bloom; C Jones; J Holland; L M Reid
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

9.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

10.  Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.

Authors:  G Schulz; L K Staffileno; R A Reisfeld; G Dennert
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.